Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1999-11-16
pubmed:abstractText
Hydroxyurea (HU), an inhibitor of ribonucleotide reductase, may potentiate the activity of 5-fluorouracil (5-FU) and folinic acid (FA) by reducing the deoxyribonucleotide pool available for DNA synthesis and repair. However as HU may inhibit the formation of 5-fluoro-2-deoxyuridine-5-monophosphate (FdUMP), one of the principal active metabolites of 5-FU, the scheduling of HU may be critical. In vitro experiments suggest that administration of HU following 5-FU, maintaining the concentration in the region of 1 mM for six or more hours, significantly enhances the efficacy of 5-FU.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
981-3
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10509162-Adenocarcinoma, pubmed-meshheading:10509162-Adult, pubmed-meshheading:10509162-Aged, pubmed-meshheading:10509162-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10509162-Colorectal Neoplasms, pubmed-meshheading:10509162-Disease-Free Survival, pubmed-meshheading:10509162-Dose-Response Relationship, Drug, pubmed-meshheading:10509162-Female, pubmed-meshheading:10509162-Fluorouracil, pubmed-meshheading:10509162-Humans, pubmed-meshheading:10509162-Hydroxyurea, pubmed-meshheading:10509162-Infusions, Intravenous, pubmed-meshheading:10509162-Leucovorin, pubmed-meshheading:10509162-Male, pubmed-meshheading:10509162-Middle Aged, pubmed-meshheading:10509162-Nucleic Acid Synthesis Inhibitors, pubmed-meshheading:10509162-Prognosis, pubmed-meshheading:10509162-Survival Rate, pubmed-meshheading:10509162-Treatment Outcome
pubmed:year
1999
pubmed:articleTitle
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
pubmed:affiliation
Imperial Cancer Research Fund Medical Oncology Unit, Churchill Hospital, Oxford, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II